Compare CGEN & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGEN | NHS |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.7M | 230.7M |
| IPO Year | 2000 | N/A |
| Metric | CGEN | NHS |
|---|---|---|
| Price | $1.74 | $7.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 568.8K | 111.8K |
| Earning Date | 03-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.44% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,903,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $164.92 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $6.95 |
| 52 Week High | $2.66 | $9.17 |
| Indicator | CGEN | NHS |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 65.17 |
| Support Level | $2.04 | $7.54 |
| Resistance Level | $2.08 | $7.64 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 1.00 | 85.37 |
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.